Previous close | 0.6713 |
Open | 0.6700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.6311 - 0.7299 |
52-week range | 0.3550 - 1.2800 |
Volume | |
Avg. volume | 172,019 |
Market cap | 24.231M |
Beta (5Y monthly) | 1.52 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2200 |
Earnings date | 30 Apr 2024 - 04 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 27 Feb 2023 |
1y target est | N/A |
Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
Qilian International Holding Group ( NASDAQ:QLI ) First Half 2023 Results Key Financial Results Revenue: US$29.2m (down...